California Prostate Cancer Coalition - CPCC

Please find the Livestream broadcast link to furnish to family members and guests who are unable to be physically present for the Funeral Service for Thomas N. Kirk.

https://hillsidememorial.livecontrol.tv/ca1bf176

The Service is scheduled for Friday March 1st at 2:00PM in the Small Chapel at Hillside Memorial Park.

LiveControl

Services for my beloved husband Tom Kirk will take place this Friday, March 1, at Hillside Memorial Park (6001 W. Centinela Ave., Los Angeles 90045) at 2:00 pm in the small chapel. Please let me know if you have any questions. Merel [email protected]

California Prostate Cancer Coalition - CPCC President Merel Grey Nissenberg at last night's National Alliance of State Prostate Cancer Coalitions dinner.

CPCC Board Member and Prostatepedia Editor Jessie Myers moderates a panel (Dr. Markowski, Dr. Morris, Dr. Armstrong, and Dr. Spratt) during the National Alliance of State Prostate Cancer Coalitions 18th Annual Meeting in DC.

Tommorow us the day.Join us for our CPCC/UCSF 3rd Patient Conference on Prostate Cancer. Reegister here for event

CPCC/UCSF Present: The 2022 Patient Conference on Prostate Cancer (virtual) CPCC and UCSF Present: The 2022 Patient Conference on Prostate Cancer (virtual)

New Aetna Policy for PSMA Screening for PLUVICTO Radioligand Therapy

http://ow.ly/M6nY50JVtX0

New Aetna Policy for PSMA Screening for PLUVICTO Radioligand Therapy Aetna Policy for PSMA Screening, Aetna Policy for PLUVICTO Radioligand Therapy, PLUVICTO Radioligand Therapy, PLUVICTO PSMA Screening for prostate cancer,

Web-Based Peer Navigation for Men with Prostate Cancer and Their Family Caregivers: A Pilot Feasibility Study.

http://ow.ly/NIPT50JVtWk

Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.

http://ow.ly/3vWq50JVtVH

Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1. Talazoparib has shown antitumor activity with a manageable safety profile in men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR)/homologous recombination repair (HRR) alterations.

Neurotoxicities of Novel Non-Steroidal Anti-Androgens for Prostate Cancer: A Systematic Review and Meta-Analysis - Beyond the Abstract

http://ow.ly/HGST50JVtVm

Variability in Testosterone Measurement Between Radioimmunoassay (RIA), Chemiluminescence Assay (CLIA) and Liquid Chromatography-Tandem Mass Spectrometry (MS) Among Prostate Cancer Patients on Androgen Deprivation Therapy (ADT) - Beyond the Abstract

http://ow.ly/Aqsf50JVtUe

Variability in Testosterone Measurement Between Radioimmunoassay (RIA), Chemiluminescence Assay (CLIA) and Liquid Chromatography-Tandem Mass Spectrometry (MS) Among Prostate Cancer Patients on Androgen Deprivation Therapy (ADT) - Beyond the Abstract testosterone levels for men on androgen deprivation therapy, castrate resistant prostate cancer (CRPC), androgen deprivation therapy (ADT), prostate cancer patients on androgen deprivation therapy (ADT), gold standard for testosterone measurement, Liquid chromatography-tandem mass spectrometry.

Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.

http://ow.ly/fpHf50JVtTB

Fusion heralds FDA tumor therapy clearance

http://ow.ly/L4U950JVtTg

Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719).

http://ow.ly/7bn250JVtSB

Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes.

http://ow.ly/NJPW50JVtRL

Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.

http://ow.ly/gK6250JVtR9

Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. To compare the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, the adapted Prostate Cancer Working Group Criteria 3 (aPCWG3), the adapted Positron Emission Tomography Response Criteria in Solid Tumors (aPERCIST), the PSMA PET Progression (PPP), and the Response Evaluation Criteria In PSMA...

Two Specialists, Two Recommendations: Discordance between Urologists' & Radiation Oncologists' Prostate Cancer Treatment Recommendations.

http://ow.ly/Rj3v50JVtQR

Two Specialists, Two Recommendations: Discordance between Urologists' & Radiation Oncologists' Prostate Cancer Treatment Recommendations. To examine the treatment recommendation patterns among urologists and radiation oncologists, the level of concordance or discordance between physician recommendations, and the association between physician recommendations and the treatment that patients received.

Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.

http://ow.ly/ZEvT50JVtQl

Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer. Docetaxel-related adverse events (AEs) such as neutropenia and febrile neutropenia (FN) can be life-threatening. A previous in vivo study raised the hypothesis that the castration status affects the rate of hematologic AEs.

Transperineal vs Transrectal Prostate Biopsy: Is One Better?

http://ow.ly/e0aA50JVtPz

Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial

http://ow.ly/vLr350JVtOQ

Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial | Future Oncology What is this summary about? This is a summary of a publication about the ARASENS trial, which was published in the New England Journal of Medicine in February 2022. The trial includes 1,306 men with a type of prostate cancer called metastatic, hormone-sensitive prostate cancer (also called mHSPC). I...

Variation and Disparity in the Use of Prostate Cancer Risk Stratification Tools in the United States.

http://ow.ly/1P6x50JVtOH

Variation and Disparity in the Use of Prostate Cancer Risk Stratification Tools in the United States. In this review we summarize evidence from US studies examining variation in the use of prostate magnetic resonance imaging (MRI) and tissue-based gene expression tests (genomic tests), focusing on sources of regional and racial variation.

PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study.

http://ow.ly/7Wfi50JVtOq

EAU 2022: Metastatic Prostate Cancer: Possible Synergies Between Radioligand and Systemic Treatment in M1 Prostate Cancer? Future Perspectives

http://ow.ly/Qkcb50JVtO9

EAU 2022: Recurrent Prostate Cancer: Salvage Treatment Options for the PSMA Avid Lesion - Radiotherapy

http://ow.ly/XVhP50JVtNt

EAU 2022: Recurrent Prostate Cancer: Treatment Landscape of Hormone Sensitive Recurring M1 Prostate Cancer

http://ow.ly/cExg50JVtMn

EAU 2022: Lifetime Risk of Prostate Cancer Death Among High-Risk Germline Mutation Carriers

http://ow.ly/TWUM50JVtLR

EAU 2022: Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy

http://ow.ly/ENEr50JVtKY

EAU 2022: Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy EAU 2022 Declan Murphy the initial results of the LuTectomy trial, LuTectomy, a single-arm study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 prior to radical prostatectomy

EAU 2022: ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix With or Without Apalutamide Prior to Radical Prostatectomy for High-Risk Prostate Cancer

http://ow.ly/JqBQ50JVtK3

EAU 2022: BRCA1/2 and ATM Mutated Metastatic Prostate Cancers May Present With Low Serum PSA

http://ow.ly/8C1g50JVtJl

EAU 2022: BRCA1/2 and ATM Mutated Metastatic Prostate Cancers May Present With Low Serum PSA EAU 2022 PSA levels at presentation for men with BRCA1/2 and ATM mutated metastatic prostate cancer. PARP inhibitors have previously shown survival benefits in mCRPC patients with homologous recombination repair (HRR) genes (BRCA1/2, and ATM) mutations

EAU 2022: The Changing Landscape of Systemic Therapy in the Treatment of Newly-Diagnosed Metastatic Prostate Cancer

http://ow.ly/l5S350JVtI2

EAU 2022: The Changing Landscape of Systemic Therapy in the Treatment of Newly-Diagnosed Metastatic Prostate Cancer EAU 2022 systemic therapy in the treatment of newly-diagnosed metastatic prostate cancer, 2nd line systemic treatment to ADT in newly-diagnosed metastatic prostate cancer

Prostate-specific antigen (PSA) and biopsy contamination in the Göteborg-1 randomized, population-based, prostate cancer screening trial.

http://ow.ly/igbl50JVtz8

Prostate-specific antigen (PSA) and biopsy contamination in the Göteborg-1 randomized, population-based, prostate cancer screening trial. Even when a screening study has demonstrated a mortality reduction, the degree of pre-testing and contamination is of importance as it can dilute the "true" effect of screening. Our object was to describe the level of pre-testing and contamination in the Göteborg-1 prostate cancer (PC...